Biosynex Cash Flow Conversion Efficiency

Latest as of June 2025: -0.160x

Biosynex cash flow conversion efficiency. Based on the latest financial reports, Biosynex (ALBIO) has a cash flow conversion efficiency ratio of -0.160x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.07 Million ≈ $-8.26 Million USD) by net assets (€44.31 Million ≈ $51.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Biosynex (2008–2024)

Cash flow conversion efficiency of Biosynex from 2008 to 2024. This chart illustrates how Biosynex's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALBIO share price today for real-time trading data and today's change.

Biosynex Cash Flow Conversion Ratio Explained

Biosynex cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Biosynex Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Biosynex ranked by their cash flow conversion efficiency. Also see market cap of Biosynex for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
SeaTwirl AB ST:STW	-0.076x
Rajshree Polypack Limited NSE:RPPL	0.072x
Heavy Minerals Ltd AU:HVY	-0.149x
Atta Global Group Bhd KLSE:7099	-0.008x
ATP 30 Public Company Limited BK:ATP30	0.090x
Mercer International Inc F:AEZ	0.154x
Energean Oil & Gas PLC LSE:ENOG	0.428x
Clean Seas Seafood Limited F:C7S	-0.016x

Annual Cash Flow Conversion Efficiency for Biosynex (2008–2024)

The table below shows the annual cash flow conversion efficiency of Biosynex from 2008 to 2024. Review Biosynex free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€80.50 Million ≈ $94.11 Million	€-10.12 Million ≈ $-11.83 Million	-0.126x	-61.91%
2023-12-31	€124.31 Million ≈ $145.34 Million	€-9.65 Million ≈ $-11.29 Million	-0.078x	-361.86%
2022-12-31	€166.76 Million ≈ $194.96 Million	€4.95 Million ≈ $5.78 Million	0.030x	-95.47%
2021-12-31	€167.81 Million ≈ $196.18 Million	€109.83 Million ≈ $128.41 Million	0.655x	+37.14%
2020-12-31	€66.29 Million ≈ $77.50 Million	€31.64 Million ≈ $36.99 Million	0.477x	+1213.25%
2019-12-31	€30.38 Million ≈ $35.52 Million	€1.10 Million ≈ $1.29 Million	0.036x	+127.67%
2018-12-31	€29.26 Million ≈ $34.21 Million	€467.12K ≈ $546.11K	0.016x	-4.82%
2017-12-31	€28.91 Million ≈ $33.80 Million	€484.82K ≈ $566.81K	0.017x	-16.59%
2016-12-31	€24.36 Million ≈ $28.48 Million	€489.91K ≈ $572.75K	0.020x	-7.96%
2015-12-31	€21.13 Million ≈ $24.70 Million	€461.66K ≈ $539.73K	0.022x	+110.31%
2009-12-31	€-341.55K ≈ $-399.30K	€72.40K ≈ $84.65K	-0.212x	-117.67%
2008-12-31	€-153.74K ≈ $-179.73K	€-184.44K ≈ $-215.63K	1.200x	--

About Biosynex

PA:ALBIO France Medical Devices

Market Cap

$17.67 Million

€15.11 Million EUR

Market Cap Rank

#25683 Global

#418 in France

Share Price

€0.82

Change (1 day)

-3.07%

52-Week Range

€0.48 - €1.57

All Time High

€25.28